These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 301055)

  • 1. Adenocarcinoma R-3327 of the Copenhagen rat as a suitable model for immunological studies of prostate cancer.
    Lopez DM; Voigt W
    Cancer Res; 1977 Jul; 37(7 Pt 1):2057-61. PubMed ID: 301055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of prostate carcinoma lines in the Copenhagen rat.
    Voigt W; Lopez DM
    Natl Cancer Inst Monogr; 1978 Dec; (49):269-73. PubMed ID: 748780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic studies of prostatic cancer using the R3327 rat model.
    Lubaroff DM; Reynolds CW; Culp DA
    Trans Am Assoc Genitourin Surg; 1978; 70():60-5. PubMed ID: 753024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Dunning R3327 prostate adenocarcinoma in the Fischer-Copenhagen F1 rat: a useful model for immunological studies.
    Claflin AJ; McKinney EC; Fletcher MA
    Oncology; 1977; 34(3):105-9. PubMed ID: 917439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel immunological model for the study of prostate cancer.
    Sharma N; Luo J; Kirschmann DA; O'Malley Y; Robbins ME; Akporiaye ET; Lubaroff DM; Heidger PM; Hendrix MJ
    Cancer Res; 1999 May; 59(10):2271-6. PubMed ID: 10344727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rat prostate carcinoma 11095-A: profile of organ- and tumor-specific antigens.
    Lande IJ; Feldbush TL; Lubaroff DM; Bonney WW
    Natl Cancer Inst Monogr; 1978 Dec; (49):283-7. PubMed ID: 86165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
    Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
    Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on a weakly immunogenic squamous cell carcinoma of the rat prostate.
    Lande IJ; Feldbush TL; Lubaroff DM
    Invest Urol; 1980 Mar; 17(5):419-24. PubMed ID: 7358506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological studies of prostate adenocarcinoma in an animal model.
    Claflin AJ; McKinney EC; Fletcher MA
    Prog Clin Biol Res; 1980; 37():365-77. PubMed ID: 7384093
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune response to a mammary adenocarcinoma. IV. Blocking of cell-mediated cytolysis by immunoglobulins binding to immune lymphocytes.
    Huber SA; Lucas ZJ
    J Immunol; 1977 Aug; 119(2):726-36. PubMed ID: 328781
    [No Abstract]   [Full Text] [Related]  

  • 11. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge.
    Friedman EJ; Orth CR; Brewton KA; Ponniah S; Alexander RB
    J Urol; 1997 Oct; 158(4):1585-8. PubMed ID: 9302178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth characteristics and immunogenicity of the R-3327 rat prostate carcinoma.
    Coffey DS; Smolev J; Heston WD; Scott WW
    Natl Cancer Inst Monogr; 1978 Dec; (49):289-91. PubMed ID: 748782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunobiology of carcinoma of the prostate.
    Catalona WJ
    Invest Urol; 1980 Mar; 17(5):373-7. PubMed ID: 6987190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective cell-mediated immunity in carcinoma of the prostate.
    Thomas JW; Jerkins G; Cox C; Lieberman P
    Invest Urol; 1976 Jul; 14(1):72-5. PubMed ID: 60303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer.
    van der Linden RR; Haagmans BL; Mongiat-Artus P; van Doornum GJ; Kraaij R; Kadmon D; Aguilar-Cordova E; Osterhaus AD; van der Kwast TH; Bangma CH
    Eur Urol; 2005 Jul; 48(1):153-61. PubMed ID: 15967266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenic determinants in a virus-induced mouse mammary tumor recognized by cell-mediated immune assays.
    Lopez PF; Parks WP; Lopez DM
    J Natl Cancer Inst; 1984 Mar; 72(3):725-32. PubMed ID: 6199544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response to a mammary adenocarcinoma. VI. Blocking of tumor-specific cell-mediated cytotoxicity by antibodies to the cytotoxic lymphocyte.
    Huber SA; Lucas ZJ
    J Immunol; 1978 Dec; 121(6):2490-6. PubMed ID: 309904
    [No Abstract]   [Full Text] [Related]  

  • 18. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
    Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
    Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An animal model for the study of prostate carcinoma.
    Lubaroff DM; Canfield L; Rasmussen GT; Reynolds CW
    Natl Cancer Inst Monogr; 1978 Dec; (49):275-81. PubMed ID: 748781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP).
    Johnson LE; Frye TP; Arnot AR; Marquette C; Couture LA; Gendron-Fitzpatrick A; McNeel DG
    Vaccine; 2006 Jan; 24(3):293-303. PubMed ID: 16115700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.